Vaporised cannabis containing both THC and CBD has been shown to reduce migraine symptoms for up to 48 hours in a world-first randomised double-blind, placebo-controlled study. This story first appeared on leafie, view here Author: Kevin Dinneen
A new initiative is giving patients a direct voice in how the UK’s medical cannabis market is shaped, as global producers look to better understand the needs of the community. Launching this month, Patient Panel is a new medical cannabis market research consultancy that aims to [...]
Research shows that oxidation, not contamination, is the leading cause of vape oil discoloration, according to a recent white paper from Abstrax Tech. Vape brands, particularly those producing high-end concentrates, have struggled to prevent product degradation in retail environments, where display refrigeration is often limited or [...]
Copyright © 2020 – 2025 | The Cannabis Pages | All Rights Reserved | Important Notice | The Cannabis Pages “TCP” is an information resource for medical cannabis patients and prescribers. Nothing on the site should be construed as a promotion or inducement. TCP does not promote any product or represent that the products mentioned on TCP’s website are treatment for any kind of medical condition. TCP cannot guarantee that information provided is error-free or complete and is not responsible for the quality of the information provided by users. Cannabis is an unlicensed medication which can only be administered under the supervision of a licensed physician.